Testing: Tissue Testing

When a biopsy is taken from a tumor, the tissue must be analyzed for cell abnormalities to determine if it is cancerous and malignant. Analysis also reveals the type of cancer the patient has.

The first type of test uses a process called flow cytometry. Flow cytometry is done in a high-tech machine. The process sorts through the cells from the biopsy and examines them for certain cell markers that are found in the membranes of cells. These markers, called clusters of differentiation (CD), identify certain types of cancer cells.

The second test examines the DNA of biopsied cells. Laboratory technicians examine DNA for genetic abnormalities. These abnormalities cause the mutations in cancerous cells, which causes them to grow faster than normal, healthy cells, thus creating a tumor. Identification of these abnormalities helps classify cancer.

Once the biopsied tissue is examined using both of these techniques, the doctor can identify the type of cancer a patient has and then perform the necessary tests to stage the disease.

These tests are also useful in determining the type of treatment to give a patient. Some cell markers bind with antibodies – "tags" that mark the cell for removal by the immune system – so immunotherapy can be used. For more information on this type of treatment, please see the article titled Monoclonal Antibody Therapy.

Dive Deeper

For more information on Hodgkin's disease, please see the following pages

For more information on Non-Hodgkin lymphoma, please see the following pages:

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap